Literature DB >> 14615745

Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report.

Mark E Wylam1, Peter M Anderson, Nancy L Kuntz, Vilmarie Rodriguez.   

Abstract

We report the successful use of anti-CD20 therapy in a child with refractory myasthenia gravis (MG), an antibody-mediated autoimmune disease, who did not respond to conventional therapy. After initiation of anti-CD20 therapy, clinical improvement (muscular strength, pulmonary function) was observed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14615745     DOI： 10.1067/S0022-3476(03)00300-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  12 in total

1.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

2.  Rituximab Treatment in Myasthaenia Gravis: Report of two paediatric cases.

Authors:  Roshan Koul; Amna Al-Futaisi; Rana Abdelrahim; Renjith Mani; Reem Abdwani; Abdullah Al-Asmi
Journal:  Sultan Qaboos Univ Med J       Date:  2018-09-09

Review 3.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 4.  [Rituximab in treatment for neuroimmunological diseases].

Authors:  A Schröder; G Ellrichmann; G Chehab; M Schneider; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

5.  Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis.

Authors:  Yan Li; Zhidan Tu; Shiguang Qian; John J Fung; Sanford D Markowitz; Linda L Kusner; Henry J Kaminski; Lina Lu; Feng Lin
Journal:  J Immunol       Date:  2014-07-23       Impact factor: 5.422

6.  Rituximab in refractory MuSK antibody myasthenia gravis.

Authors:  Mona Thakre; Jihad Inshasi; Mahmoud Marashi
Journal:  J Neurol       Date:  2007-04-30       Impact factor: 4.849

Review 7.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

Authors:  Raffaele Iorio; Valentina Damato; Paolo Emilio Alboini; Amelia Evoli
Journal:  J Neurol       Date:  2014-10-12       Impact factor: 4.849

8.  Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation.

Authors:  Vern C Juel; Janice M Massey
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

9.  Juvenile myasthenia gravis: a paediatric perspective.

Authors:  Maria F Finnis; Sandeep Jayawant
Journal:  Autoimmune Dis       Date:  2011-11-01

10.  A Sensitive Method for Detecting Peptide-specific CD4+ T Cell Responses in Peripheral Blood from Patients with Myasthenia Gravis.

Authors:  Sapna Sharma; Clas Malmeström; Christopher Lindberg; Sarah Meisel; Karin Schön; Martina Verolin; Nils Yngve Lycke
Journal:  Front Immunol       Date:  2017-10-24       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.